德国辅助治疗组间淋巴结阳性研究(GAIN):比较两种剂量密集方案(iddEPC与ddEC-PwX)治疗高危早期乳腺癌患者的III期试验
GAIN III期试验将2994例腋窝淋巴结阳性的高危早期乳腺癌患者随机分配至iddEPC方案或ddEC-PwX方案,中位随访74个月,5年无病生存率分别为80.2%与81.7%(HR=0.95,95%CI 0.81-1.11,P=0.49),5年总生存率分别为89.0%与89.4%(HR=0.85,95%CI 0.69-1.04,P=0.10)。结论认为在ddEC-Pw基础上加用卡培他滨未改善结局,反而增加毒性,不应推荐进一步使用。
要点
- iddEPC组血液学3-4级不良事件更常见(P<0.001),ddEC-PwX组非血液学毒性更常见(P=0.04)。
- 5年无病生存率ddEC-PwX组81.7% vs iddEPC组80.2%,HR=0.95(95%CI 0.81-1.11,P=0.49)。
- 5年总生存率ddEC-PwX组89.4% vs iddEPC组89.0%,HR=0.85(95%CI 0.69-1.04,P=0.10)。
核心结论
- 在ddEC-Pw基础上加用卡培他滨与iddEPC相比未改善结局,反而增加毒性,不应推荐进一步使用。
研究设计与样本
- 德国辅助治疗组间淋巴结阳性(GAIN)III期随机试验,2004年6月至2008年8月共随机分配2994例患者,iddEPC组1498例,ddEC-PwX组1496例并开始治疗。
- 入组者为年龄18岁且生物学年龄<65岁、组织学证实腋窝淋巴结阳性的女性。
主要发现
- 中位随访74个月,记录645例事件和383例死亡。
- 3-4级血液学不良事件在iddEPC组更常见(P<0.001),非血液学不良事件在ddEC-PwX组更常见(P=0.04)。
- 5年估计无病生存率ddEC-PwX组为81.7%(95%CI 79.5-83.6),iddEPC组为80.2%(95%CI 78.0-82.2),HR=0.95(95%CI 0.81-1.11,log-rank P=0.49)。
- 5年总生存率ddEC-PwX组为89.4%(95%CI 87.7-91.0),iddEPC组为89.0%(95%CI 87.2-90.6),HR=0.85(95%CI 0.69-1.04,log-rank P=0.10)。
关键数值与推荐
- iddEPC方案:表柔比星150 mg/m2、紫杉醇225 mg/m2、环磷酰胺2500 mg/m2(入组1200例后减至2000 mg/m2),每2周静脉给药,共3疗程。
- ddEC-PwX方案:ddEC(表柔比星112.5 mg/m2+环磷酰胺600 mg/m2,静脉每2周,共4周期)序贯每周紫杉醇(67.5 mg/m2静脉每8天,共10周)联合卡培他滨(2000 mg/m2口服,第1-14天,每22天,共4周期)。
- 进一步随机分配患者接受伊班膦酸2年 vs 观察,以及培非格司亭第2天 vs 第4天。
临床怎么用
- 作者结论认为在ddEC-Pw基础上加用卡培他滨未改善结局且增加毒性,不应推荐进一步使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dose-dense (dd) regimens are one of the preferred options for the adjuvant treatment of breast cancer patients with intermediate to high risk. The German Adjuvant Intergroup Node-positive trial aimed at optimizing intense dd (idd) strategies by evaluating drug combinations and the addition of capecitabine. PATIENTS AND METHODS: Women (aged 18 years and biologically <65 years) with histologically involved axillary lymph nodes were randomly assigned to receive three courses each of epirubicin (E) 150 mg/m2, paclitaxel (P) 225 mg/m2 and cyclophosphamide (C) 2500 mg/m2 (reduced to 2000 mg/m2 after recruitment of 1200 patients) q2w intravenously (i.v.) (iddEPC-regimen) or ddEC (E 112.5 mg/m2 + C 600 mg/m2, i.v. q2w for 4 cycles) followed by paclitaxel weekly (Pw 67.5 mg/m2 i.v. q8d for 10 weeks) plus capecitabine (X 2000 mg/m2 p.o. days 1-14, q22 for 4 cycles) (ddEC-PwX-regimen). Further randomization assigned patients to ibandronate for 2 years versus observation and to pegfilgrastim day 2 versus 4. RESULTS: From June 2004 to August 2008, 2994 patients were randomized to either iddEPC (N = 1498), or ddEC-PwX (N = 1496) and started treatment. Median age was 50 years; pN1 (37.8%), pN2 (35.3%); pN3 (26.9%); 46.4% were G3 tumors; 76.9% hormone receptor-positive and 22% HER2-positive. After a median follow-up of 74 months, 645 events and 383 deaths were recorded. Hematological adverse events grades 3-4 were more common with iddEPC (P < 0.001), nonhematological with ddEC-PwX (P = 0.04), even if the toxicity profile of the two regimens was different. At 5 years, estimated disease-free survival rates for ddEC-PwX and iddEPC were 81.7% [95% confidence interval (CI) 79.5-83.6] versus 80.2% (95% CI 78.0-82.2). Hazard ratio (HR)=0.95 (95% CI 0.81-1.11, log-rank P = 0.49). Five-year overall survival rates were 89.4% for ddEC-PwX (95% CI 87.7-91.0) and 89.0% for iddEPC (95% CI 87.2-90.6), HR = 0.85 (95% CI 0.69-1.04, log-rank P = 0.10). CONCLUSION: Adding capecitabine to ddEC-Pw did not improve outcome in comparison to iddEPC but increased toxicity and should not be recommended for further use.
引用
- Möbus V, von Minckwitz G, Jackisch C, et al. German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients. Ann Oncol. 2017. PMID: 28459941. doi:10.1093/annonc/mdx203
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。